Multidrug resistant Staphylococcus aureus (e.g., methicillin resistant [MRSA]) and enterococci (e.g., vancomycin resistant [VRE]) emerged in the 1960's and 1980's, and are leading causes of life-threatening infection in the hospital - more recently also in the community. Critically, after 20 years of containment, vancomycin resistance moved from VRE to MRSA, creating VRSA, and there are now 10 well documented cases. The overall goal of this program project is to identify and develop new drugs for treating infections caused by VRSA and VRE. This will be conducted hand-in-hand with studies to understand the development and proliferation of resistance in the multidrug resistant microbes being targeted in this Subproject. Overarching Goals: Determine what genetic or biological events led to the breach of containment of vancomycin resistance in VRE and transfer to VRSA, and demonstrate the activity of new compounds against them, by discovering and examining: -a known genetic event (insertional inactivation of a plasmid borne postsegregational killing TA module), - unknown traits within the genomes of the 10 well documented VRSA strains, and the putative VRE donors coisolated with them, - genetic and metabolic compatibilities, that may have predisposed them to coexist in mixed infection or participate in vancomycin resistance transfer, and - the efficacy of compounds developed in this PPG against these highly multidrug resistant, hospital adapted strains By understanding the basis for transfer as well as the nature of these increasingly resistant strains, we will be better positioned to assess the threat of continued erosion of antibiotic sensitivity in leading causes of hospital and community infection in the US, and will be alert to the types of conditions that promote this transfer.
MRSA infections are common, often invasive and life threatening. VRE are leading causes of hospital acquired infection. VRE now have donated vancomycin resistance to MRSA, creating VRSA refractor to this last line antibiotic. This research aims to understand these multidrug resistant strains and the resistance transmission, and assess the efficacy of novel compounds against them.
|Rajagopal, Mithila; Martin, Melissa J; Santiago, Marina et al. (2016) Multidrug Intrinsic Resistance Factors in Staphylococcus aureus Identified by Profiling Fitness within High-Diversity Transposon Libraries. MBio 7:|
|Cheesman, Hilary K; Feinbaum, Rhonda L; Thekkiniath, Jose et al. (2016) Aberrant Activation of p38 MAP Kinase-Dependent Innate Immune Responses Is Toxic to Caenorhabditis elegans. G3 (Bethesda) 6:541-9|
|Matano, Leigh M; Morris, Heidi G; Wood, B McKay et al. (2016) Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening. Bioorg Med Chem 24:6307-6314|
|Selleck, Elizabeth M; Gilmore, Michael S (2016) Oxygen as a Virulence Determinant in Polymicrobial Infections. MBio 7:|
|Gaca, Anthony O; Gilmore, Michael S (2016) Killing of VRE Enterococcus faecalis by commensal strains: Evidence for evolution and accumulation of mobile elements in the absence of competition. Gut Microbes 7:90-6|
|Pasquina, Lincoln; Santa Maria Jr, John P; McKay Wood, B et al. (2016) A synthetic lethal approach for compound and target identification in Staphylococcus aureus. Nat Chem Biol 12:40-5|
|Kim, Wooseong; Fricke, Nico; Conery, Annie L et al. (2016) NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption. Future Med Chem 8:257-69|
|Rajagopal, Mithila; Walker, Suzanne (2016) Envelope Structures of Gram-Positive Bacteria. Curr Top Microbiol Immunol :|
|Newman, Martin; Ausubel, Frederick M (2016) Introduction to Gene Editing and Manipulation Using CRISPR/Cas9 Technology. Curr Protoc Mol Biol 115:31.4.1-6|
|Van Tyne, Daria; Ciolino, Joseph B; Wang, Jay et al. (2016) Novel Phagocytosis-Resistant Extended-Spectrum Î²-Lactamase-Producing Escherichia coli From Keratitis. JAMA Ophthalmol 134:1306-1309|
Showing the most recent 10 out of 97 publications